Optimizing Survival of Patients With Marginally Operable Stage IIIA Non–Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery

Kai Lin Yang, Yih Chen Chang, Hui Ling Ko, Mau Shin Chi, Hsin Ell Wang, Pei Sung Hsu, Chen Chun Lin, Diana Yu Wung Yeh, Shang Jyh Kao, Jiunn Song Jiang, Kwan Hwa Chi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Micro-Abstract The management of marginally operable stage IIIA non–small-cell lung cancer is controversial. We established a phased concurrent chemoradiotherapy (CCRT) protocol offering neoadjuvant CCRT followed by surgery or, for reassessed inoperable patients, maintenance chemotherapy and split-course CCRT boost. Survival of the patients receiving neoadjuvant CCRT and surgery was optimized. Survival of the reassessed inoperable patients receiving split-course CCRT was acceptable.

Original languageEnglish
Pages (from-to)550-557
Number of pages8
JournalClinical Lung Cancer
Volume17
Issue number6
DOIs
Publication statusPublished - Nov 1 2016
Externally publishedYes

Keywords

  • Chemoradiotherapy
  • Marginally operable
  • Non–small cell lung cancer
  • Stage IIIA
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Optimizing Survival of Patients With Marginally Operable Stage IIIA Non–Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery'. Together they form a unique fingerprint.

  • Cite this

    Yang, K. L., Chang, Y. C., Ko, H. L., Chi, M. S., Wang, H. E., Hsu, P. S., Lin, C. C., Yeh, D. Y. W., Kao, S. J., Jiang, J. S., & Chi, K. H. (2016). Optimizing Survival of Patients With Marginally Operable Stage IIIA Non–Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery. Clinical Lung Cancer, 17(6), 550-557. https://doi.org/10.1016/j.cllc.2016.05.013